Search Result

Results for "

retinal diseases

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (2) Autophagy (2) Cannabinoid Receptor (2) Drug Metabolite (2) E3 Ligase Ligand-Linker Conjugates (5) FGFR (1) Glucocorticoid Receptor (1) GPR109A (2) Isotope-Labeled Compounds (1) NF-κB (2) Reactive Oxygen Species (2) ROCK (2) SRPK (1) Succinate Receptor 1 (1) VEGFR (4)
By Research Areas:	Cancer (10) Cardiovascular Disease (4) Endocrinology (1) Inflammation/Immunology (14) Metabolic Disease (1) Neurological Disease (5)

Inhibitors & Agonists

Inhibitory Antibodies

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-153569

ROCK-IN-7	ROCK	Others
ROCK-IN-7 (compound 9) is a ROCK kinase inhibitor. ROCK-IN-7 can be used for research in ocular diseases (such as glaucoma and retinal diseases) .

HY-153564

ROCK-IN-6	ROCK	Inflammation/Immunology
ROCK-IN-6 is a potent and selectiveROCK2 inhibitor with an IC₅₀ of 2.19 nM. ROCK-IN-6 is extracted from patent WO2021164351 A1, example 7, has the potential for glaucoma and retinal diseases research .

HY-W556870

OT-551	NF-κB	Inflammation/Immunology
OT-551 is a NF-κB inhibitor with antioxidant and anti-inflammatory effects. OT-551 has the potential for retinal diseases research .

HY-W751734

HU 433	Cannabinoid Receptor	Others Neurological Disease Inflammation/Immunology
HU 433 is a synthetic cannabinoid CB2 receptor agonist and is the enantiomer of HU 308 (HY-161510). HU 433 exerts its anti-inflammatory and neuroprotective effects by binding to CB2 receptors. HU 433 can be used in the study of neuroinflammation and retinal diseases .

HY-161578

Dithio-CN03	Others	Neurological Disease
Dithio-CN03 is a compound with the highest neuroprotective efficacy. Dithio-CN03 fights the progression of retinitis pigmentosa (RP) by inhibiting the cGMP mediated signaling pathway and reducing photoreceptor cell death. Dithio-CN03 can be used in research into RP and other retinal degenerative diseases .

HY-153567

Immune cell migration-IN-2	Others	Inflammation/Immunology
Immune cell migration-IN-2 is a potent immune cell migration inhibitor with an EC₅₀ of 13.5 nM in a T-cell adhesion assay. Immune cell migration-IN-2 is extracted from patent WO2019001171, example 11, can be used for dry-eye and other retinal diseases research . Immune cell migration-IN-2 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-161510

HU-308	Cannabinoid Receptor	Others Neurological Disease
HU-308 is a highly selective CB2 receptor agonist belonging to the synthetic cannabinoid analogues. The affinity of HU-308 to CB2 receptor is more than 440 times higher than that of CB1 receptor. CB2 receptors are mainly distributed in immune cells and are responsible for regulating the immunosuppressive effects of the endocannabinoid system (ECS). HU-308 has anti-inflammatory, neuroprotective and bioactive properties that regulate microglia function. HU-308 can be used in the study of neuroinflammation and retinal diseases .

HY-103252

Monomethyl fumarate 3 Publications Verification	GPR109A Drug Metabolite	Neurological Disease Inflammation/Immunology
Monomethyl fumarate, an active metabolite of Dimethyl fumarate (DMF), is a potent GPR109A agonist. Monomethyl fumarate has the potential for multiple neuroprotective pathways and other models of retinal disease .

HY-103252S1

Monomethyl fumarate-d5	Isotope-Labeled Compounds GPR109A Drug Metabolite	Neurological Disease Inflammation/Immunology
Monomethyl fumarate-d₅ is deuterium labeled Monomethyl fumarate. Monomethyl fumarate, an active metabolite of Dimethyl fumarate (DMF), is a potent GPR109A agonist. Monomethyl fumarate has the potential for multiple neuroprotective pathways and other models of retinal disease[1][2][3].

HY-134928

Pyridinium bisretinoid A2E A2E	Apoptosis Autophagy Reactive Oxygen Species	Cancer
Pyridinium bisretinoid A2E (A2E) is a fluorophore that can be isolated from lipofuscin in the retinal pigment epithelium (RPE). Pyridinium bisretinoid A2E is an initiator of blue-light-induced apoptosis. Photoactivation of Pyridinium bisretinoid A2E mediates autophagy and the production of reactive oxygen species. Pyridinium bisretinoid A2E can be used in the study of retinal degenerative diseases .

HY-135808

BIZ 114	NF-κB	Inflammation/Immunology
BIZ 114 (Example 11) is a fatty acid derivative and potent inhibits the TNF-α activated NF-κΒ pathway. BIZ 114 has the potential to prevent and / or treat ophthalmic disorders such as retinal degenerative disorders and ocular inflammatory diseases .

HY-134928A

Pyridinium bisretinoid A2E TFA A2E TFA	Apoptosis Autophagy Reactive Oxygen Species	Cancer
Pyridinium bisretinoid A2E (A2E) TFA is a fluorophore that can be isolated from lipofuscin in the retinal pigment epithelium (RPE). Pyridinium bisretinoid A2E TFA is an initiator of blue-light-induced apoptosis. Photoactivation of Pyridinium bisretinoid A2E TFA mediates autophagy and the production of reactive oxygen species. Pyridinium bisretinoid A2E TFA can be used in the study of retinal degenerative diseases .

HY-B0636

Triamcinolone acetonide 4 Publications Verification	Glucocorticoid Receptor FGFR	Inflammation/Immunology Endocrinology Cancer
Triamcinolone acetonide inhibits basic fibroblast growth factor (bFGF) induced proliferation of retinal endothelial cells. Triamcinolone acetonide reduces chondrocyte viability and leads to cartilage destruction. Triamcinolone acetonide activates macrophage with anti-inflammatory characteristics. Triamcinolone acetonide can be used in the study of diseases such as atopic dermatitis .

HY-108798

Ziv-aflibercept	VEGFR	Cardiovascular Disease Cancer
Ziv-aflibercept is a soluble inhibitor of vascular endothelial growth factor (VEGF). Ziv-aflibercept is an adaptive variant of Aflibercept (HY-108801), Ziv-aflibercept has a low PH value and high osmotic pressure when compared to Aflibercept. Ziv-aflibercept has potential applications in metastatic colorectal carcinoma and retinal diseases .

HY-P99416

Abicipar pegol AGN-150998; MP0112	VEGFR	Cardiovascular Disease Inflammation/Immunology
Abicipar pegol (AGN-150998, MP0112) is an anti-VEGF DARPin molecule, a novel class of small proteins containing ankyrin repeat domains engineered to bind with high specificity and affinity to target proteins. Abicipar pegol effectively inhibits angiogenesis and vascular permeability and is used in the study of diseases related to ocular inflammation by intravitreal injection, reducing mean retinal thickness and leakage area .

HY-145919

hGPR91 antagonist 3	Succinate Receptor 1	Cardiovascular Disease Inflammation/Immunology
hGPR91 antagonist 3 (Compound 5g) is a potent and orally active GPR91 antagonist with IC₅₀s of 35 nM and 135 nM, for human GPR91 and rat GPR91, respectively .

HY-P99116

Faricimab RG7716	VEGFR	Metabolic Disease
Faricimab is a bispecific antibody targeting angiopoietin-2 and vascular endothelial growth factor-A (VEGF-A). Faricimab can be used for diabetic macular edema (DME) research .

HY-117661

SPHINX31 5 Publications Verification	SRPK VEGFR	Cardiovascular Disease Cancer
SPHINX31 is a potent and selective SRPK1 inhibitor, with an IC₅₀ of 5.9 nM. SPHINX31 inhibits phosphorylation of serine/arginine-rich splicing factor 1 (SRSF1). SPHINX31 also decreases the mRNA expression of pro-angiogenic VEGF-A₁₆₅a isoform. SPHINX31 can be used to research neovascular eye disease .

HY-133487

(S,R,S)-AHPC-C8-NH2 dihydrochloride VH032-C8-NH2 dihydrochloride	E3 Ligase Ligand-Linker Conjugates	Inflammation/Immunology Cancer
(S,R,S)-AHPC-C8-NH2 dihydrochloride (VH032-C8-NH2 dihydrochloride) is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used for AKT PROTAC degrader. (S,R,S)-AHPC-C8-NH2 is XF038-164A, example 8, extracted from patent WO2019173516A1 .

HY-133487B

(S,R,S)-AHPC-C8-NH2 VH032-C8-NH2	E3 Ligase Ligand-Linker Conjugates	Inflammation/Immunology Cancer
(S,R,S)-AHPC-C8-NH2 (VH032-C8-NH2) is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used for AKT PROTAC degrader. (S,R,S)-AHPC-C8-NH2 is XF038-164A, example 8, extracted from patent WO2019173516A1 .

HY-136006A

(S,R,S)-AHPC-C6-NH2 hydrochloride VH032-C6-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugates	Inflammation/Immunology Cancer
(S,R,S)-AHPC-C6-NH2 hydrochloride (VH032-C6-NH2 hydrochloride) is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used for AKT PROTAC degrader. (S,R,S)-AHPC-C6-NH2 hydrochloride is XF038-161A, example 6, extracted from patent WO2019173516A1 .

HY-136006

(S,R,S)-AHPC-C6-NH2 dihydrochloride VH032-C6-NH2 dihydrochloride	E3 Ligase Ligand-Linker Conjugates	Inflammation/Immunology Cancer
(S,R,S)-AHPC-C6-NH2 dihydrochloride (VH032-C6-NH2 dihydrochloride) is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used for AKT PROTAC degrader. (S,R,S)-AHPC-C6-NH2 dihydrochloride is XF038-161A, example 6, extracted from patent WO2019173516A1 .

HY-133487A

(S,R,S)-AHPC-C8-NH2 hydrochloride VH032-C8-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-C8-NH2 (VH032-C8-NH2) hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used in PROTAC technology .

Cat. No.	Product Name	Target	Research Area

HY-108798

Ziv-aflibercept	VEGFR	Cardiovascular Disease Cancer
Ziv-aflibercept is a soluble inhibitor of vascular endothelial growth factor (VEGF). Ziv-aflibercept is an adaptive variant of Aflibercept (HY-108801), Ziv-aflibercept has a low PH value and high osmotic pressure when compared to Aflibercept. Ziv-aflibercept has potential applications in metastatic colorectal carcinoma and retinal diseases .

HY-P99116

Faricimab RG7716	VEGFR	Metabolic Disease
Faricimab is a bispecific antibody targeting angiopoietin-2 and vascular endothelial growth factor-A (VEGF-A). Faricimab can be used for diabetic macular edema (DME) research .

HY-P99416

Abicipar pegol AGN-150998; MP0112	VEGFR	Cardiovascular Disease Inflammation/Immunology
Abicipar pegol (AGN-150998, MP0112) is an anti-VEGF DARPin molecule, a novel class of small proteins containing ankyrin repeat domains engineered to bind with high specificity and affinity to target proteins. Abicipar pegol effectively inhibits angiogenesis and vascular permeability and is used in the study of diseases related to ocular inflammation by intravitreal injection, reducing mean retinal thickness and leakage area .

Cat. No.	Product Name	Chemical Structure

HY-103252S1

Monomethyl fumarate-d5
Monomethyl fumarate-d₅ is deuterium labeled Monomethyl fumarate. Monomethyl fumarate, an active metabolite of Dimethyl fumarate (DMF), is a potent GPR109A agonist. Monomethyl fumarate has the potential for multiple neuroprotective pathways and other models of retinal disease[1][2][3].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.